Alex Bard Sells 500,000 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) Director Alex Bard sold 500,000 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $11.55, for a total value of $5,775,000.00. Following the completion of the transaction, the director now directly owns 296,878 shares in the company, valued at $3,428,940.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Hims & Hers Health Price Performance

NYSE HIMS opened at $10.36 on Friday. The stock has a market capitalization of $2.16 billion, a PE ratio of -32.38 and a beta of 0.49. The business has a 50 day simple moving average of $8.13 and a two-hundred day simple moving average of $6.61. Hims & Hers Health, Inc. has a 1-year low of $2.72 and a 1-year high of $12.04.

Hims & Hers Health (NYSE:HIMS – Get Rating) last released its quarterly earnings results on Monday, February 27th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02. The business had revenue of $167.30 million during the quarter, compared to analysts’ expectations of $161.18 million. Hims & Hers Health had a negative return on equity of 20.69% and a negative net margin of 12.47%. The firm’s revenue for the quarter was up 97.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.11) EPS. On average, analysts anticipate that Hims & Hers Health, Inc. will post -0.14 EPS for the current fiscal year.

Analysts Set New Price Targets

HIMS has been the topic of several research reports. Jefferies Financial Group raised Hims & Hers Health from a “hold” rating to a “buy” rating and raised their target price for the stock from $7.00 to $11.00 in a research report on Thursday, February 9th. Guggenheim reissued a “buy” rating and issued a $15.00 target price on shares of Hims & Hers Health in a research report on Tuesday, February 28th. Tigress Financial raised their price objective on Hims & Hers Health from $11.00 to $12.00 in a research note on Tuesday, January 10th. Piper Sandler raised their price objective on Hims & Hers Health from $7.00 to $10.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 28th. Finally, Truist Financial raised their price objective on Hims & Hers Health from $7.00 to $12.00 and gave the stock a “hold” rating in a research note on Tuesday, February 28th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $11.55.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors have recently added to or reduced their stakes in the company. Point72 Middle East FZE purchased a new position in shares of Hims & Hers Health in the 4th quarter worth approximately $29,000. Captrust Financial Advisors boosted its holdings in shares of Hims & Hers Health by 1,827.4% in the 1st quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock worth $36,000 after purchasing an additional 6,414 shares during the period. Lazard Asset Management LLC purchased a new position in shares of Hims & Hers Health in the 3rd quarter worth approximately $51,000. Tower Research Capital LLC TRC boosted its holdings in shares of Hims & Hers Health by 70.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 9,538 shares of the company’s stock worth $54,000 after purchasing an additional 3,933 shares during the period. Finally, ProShare Advisors LLC purchased a new position in shares of Hims & Hers Health in the 2nd quarter worth approximately $62,000. Hedge funds and other institutional investors own 45.60% of the company’s stock.

About Hims & Hers Health

(Get Rating)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.